{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,24]],"date-time":"2026-01-24T15:01:23Z","timestamp":1769266883548,"version":"3.49.0"},"reference-count":25,"publisher":"BMJ","issue":"1","license":[{"start":{"date-parts":[[2018,5,29]],"date-time":"2018-05-29T00:00:00Z","timestamp":1527552000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000738","name":"U.S. Department of Veterans Affairs","doi-asserted-by":"publisher","award":["1I01BX001619-01A1"],"award-info":[{"award-number":["1I01BX001619-01A1"]}],"id":[{"id":"10.13039\/100000738","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["GM081061"],"award-info":[{"award-number":["GM081061"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["AI55397"],"award-info":[{"award-number":["AI55397"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["CA090217"],"award-info":[{"award-number":["CA090217"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["AI48785"],"award-info":[{"award-number":["AI48785"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["j. immunotherapy cancer"],"published-print":{"date-parts":[[2018,12]]},"DOI":"10.1186\/s40425-018-0358-2","type":"journal-article","created":{"date-parts":[[2018,5,29]],"date-time":"2018-05-29T15:21:41Z","timestamp":1527607301000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Co-transfer of tumor-specific effector and memory CD8+ T cells enhances the efficacy of adoptive melanoma immunotherapy in a mouse model"],"prefix":"10.1136","volume":"6","author":[{"given":"Amanda","family":"Contreras","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Megan V.","family":"Beems","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrew J.","family":"Tatar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Siddhartha","family":"Sen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Prakrithi","family":"Srinand","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Suresh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tahra K.","family":"Luther","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Clifford S.","family":"Cho","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2018,5,29]]},"reference":[{"key":"358_CR1","doi-asserted-by":"publisher","first-page":"4550","DOI":"10.1158\/1078-0432.CCR-11-0116","volume":"17","author":"SA Rosenberg","year":"2011","unstructured":"Rosenberg SA, Yang JC, Sherry RM, Kammula US, Hughes MS, Phan GQ, et al. Durable complete responses in heavily pretreated patients with metastatic melanoma using T-cell transfer immunotherapy. Clin Cancer Res. 2011;17:4550\u20137.","journal-title":"Clin Cancer Res"},{"key":"358_CR2","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1038\/nri778","volume":"2","author":"SM Kaech","year":"2002","unstructured":"Kaech SM, Wherry EJ, Ahmed R. Effector and memory T-cell differentiation: implications for vaccine development. Nat Rev Immunol. 2002;2:251\u201362.","journal-title":"Nat Rev Immunol"},{"key":"358_CR3","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1016\/j.immuni.2007.08.007","volume":"27","author":"SM Kaech","year":"2007","unstructured":"Kaech SM, Wherry EJ. Heterogeneity and cell-fate decisions in effector and memory CD8+ T cell differentiation during viral infection. Immunity. 2007;27:393\u2013405.","journal-title":"Immunity"},{"key":"358_CR4","doi-asserted-by":"publisher","first-page":"1616","DOI":"10.1172\/JCI24480","volume":"115","author":"L Gattinoni","year":"2005","unstructured":"Gattinoni L, Klebanoff CA, Palmer DC, Wrzesinski C, Kerstann K, Yu Z, et al. Acquisition of full effector function in vitro paradoxically impairs the in vivo antitumor efficacy of adoptively transferred CD8+ T cells. J Clin Invest. 2005;115:1616\u201326.","journal-title":"J Clin Invest"},{"key":"358_CR5","first-page":"651","volume":"35","author":"CA Klebanoff","year":"2012","unstructured":"Klebanoff CA, Gattinoni L, Restifo NP. Sorting through subsets. Which T cell populations mediate highly effective adoptive immunotherapy? J Immunother. 2012;35:651\u201360.","journal-title":"Which T cell populations mediate highly effective adoptive immunotherapy? J Immunother"},{"key":"358_CR6","doi-asserted-by":"publisher","first-page":"9571","DOI":"10.1073\/pnas.0503726102","volume":"102","author":"CA Klebanoff","year":"2005","unstructured":"Klebanoff CA, Gattinoni L, Torabi-Parizi P, Kerstann K, Cardones AR, Finkelstein SE, et al. Central memory self\/tumor-reactive CD8+ T cells confer superior antitumor immunity compared with effector memory T cells. Proc Natl Acad Sci U S A. 2005;102:9571\u20136.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"358_CR7","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1007\/s00262-016-1823-8","volume":"65","author":"A Contreras","year":"2016","unstructured":"Contreras A, Sen S, Tatar AJ, Mahvi DA, Meyers JV, Srinand P, et al. Enhanced local and systemic anti-melanoma CD8+ T cell responses after memory T cell-based adoptive immunotherapy in mice. Cancer Immunol Immunother. 2016;65:601\u201311.","journal-title":"Cancer Immunol Immunother"},{"key":"358_CR8","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1007\/s00262-012-1326-1","volume":"62","author":"L Wentworth","year":"2013","unstructured":"Wentworth L, Meyers JV, Alam S, Russ AJ, Suresh M, Cho CS. Memory T cells are uniquely resistant to melanoma-induced suppression. Cancer Immunol Immunother. 2013;62:149\u201359.","journal-title":"Cancer Immunol Immunother"},{"key":"358_CR9","doi-asserted-by":"publisher","first-page":"3848","DOI":"10.1245\/s10434-011-1667-6","volume":"18","author":"AJ Russ","year":"2011","unstructured":"Russ AJ, Wentworth L, Xu K, Seroogy CM, Rakhmilevich A, Sondel PM, et al. Suppression of T-cell expansion by melanoma is exerted on resting cells. Ann Surg Oncol. 2011;18:3848\u201357.","journal-title":"Ann Surg Oncol"},{"key":"358_CR10","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1016\/j.cellimm.2011.06.011","volume":"271","author":"AJ Russ","year":"2011","unstructured":"Russ AJ, Xu K, Wentworth L, Alam S, Meyers JV, Macklin MD, et al. Melanoma-induced suppression of tumor antigen-specific T cell expansion is comparable to suppression of global T cell expansion. Cell Immunol. 2011;271:104\u20139.","journal-title":"Cell Immunol"},{"key":"358_CR11","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1172\/JCI81217","volume":"126","author":"CA Klebanoff","year":"2016","unstructured":"Klebanoff CA, Scott CD, Leonardi AJ, Yamamoto TN, Cruz AC, Ouyang C, et al. Memory T cell-driven differentiation of na\u00efve cells impairs adoptive immunotherapy. J Clin Invest. 2016;126:318\u201334.","journal-title":"J Clin Invest"},{"issue":"2","key":"358_CR12","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1097\/CJI.0000000000000064","volume":"38","author":"DA Mahvi","year":"2015","unstructured":"Mahvi DA, Meyers JV, Tatar AJ, Contreras A, Suresh M, Leverson GE, et al. CTLA-4 blockade plus adoptive T cell transfer promotes optimal melanoma immunity in mice. J Immunother. 2015;38(2):54\u201361.","journal-title":"J Immunother"},{"key":"358_CR13","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3389\/fonc.2013.00090","volume":"3","author":"G Schiavoni","year":"2013","unstructured":"Schiavoni G, Gabriele L, Mattei F. The tumor microenvironment: a pitch for multiple players. Front Oncol. 2013;3:1\u201315.","journal-title":"Front Oncol"},{"key":"358_CR14","doi-asserted-by":"publisher","first-page":"5451","DOI":"10.4049\/jimmunol.1490019","volume":"192","author":"SA Rosenberg","year":"2014","unstructured":"Rosenberg SA. IL-2: the first effective immunotherapy for human cancer. J Immunol. 2014;192:5451\u20138.","journal-title":"J Immunol"},{"key":"358_CR15","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1089\/hum.2007.0171","volume":"19","author":"B Heemskerk","year":"2008","unstructured":"Heemskerk B, Liu K, Dudley ME, Johnson LA, Kaiser A, Downey S, et al. Adoptive cell transfer for patients with melanoma, using tumor-infiltrating lymphocytes genetically engineered to secrete interleukin-2. Hum Gene Ther. 2008;19:496\u2013510.","journal-title":"Hum Gene Ther"},{"key":"358_CR16","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0131242","volume":"10","author":"S Tahtinen","year":"2015","unstructured":"Tahtinen S, Kaikkonen S, Merisalo-Soikkeli M, Gronerg-Vaha-Koskela S, Kanerva A, Parviainen S, et al. Favorable alteration of tumor microenvironment by immunomodulatory cytokines for efficient T-cell therapy in solid tumors. PLoS One. 2015;10:e0131242.","journal-title":"PLoS One"},{"key":"358_CR17","doi-asserted-by":"publisher","first-page":"5051","DOI":"10.4049\/jimmunol.171.10.5051","volume":"171","author":"C Jackaman","year":"2013","unstructured":"Jackaman C, Bundell CS, Kinnear BF, Smith AM, Filion P, van Hagen D, et al. IL-2 intratumoral immunotherapy enhances CD8+ T cells that mediate destruction of tumor cells and tumor-associated vasculature: a novel mechanism for IL-2. J Immunol. 2013;171:5051\u201363.","journal-title":"J Immunol"},{"key":"358_CR18","doi-asserted-by":"publisher","first-page":"1969","DOI":"10.1073\/pnas.0307298101","volume":"101","author":"CA Klebanoff","year":"2004","unstructured":"Klebanoff CA, Finkelstein SE, Surman DR, Lichtman MK, Gattinoni L, Theoret MR, et al. IL-15 enhances the in vivo antitumor activity of tumor-reactive CD8+ T cells. Proc Natl Acad Sci U S A. 2004;101:1969\u201374.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"358_CR19","doi-asserted-by":"publisher","first-page":"1565","DOI":"10.1007\/s00262-009-0666-y","volume":"58","author":"HK Le","year":"2009","unstructured":"Le HK, Graham L, Miller CH, Kmieciak M, Manjili MH, Bear HD. Incubation of antigen-sensitized T lymphocytes activated with bryostatin 1 + ionomycin in IL-7 + IL-15 increases yield of cells capable of inducing regression of melanoma metastases compared to culture in IL-2. Cancer Immunol Immunother. 2009;58:1565\u201376.","journal-title":"Cancer Immunol Immunother"},{"key":"358_CR20","doi-asserted-by":"publisher","first-page":"4479","DOI":"10.1172\/JCI69589","volume":"123","author":"M Sukumar","year":"2013","unstructured":"Sukumar M, Liu J, Ji Y, Subramanian M, Crompton JG, Yu Z, et al. Inhibiting glycolytic metabolism enhances CD8+ T cell memory and antitumor function. J Clin Invest. 2013;123:4479\u201388.","journal-title":"J Clin Invest"},{"key":"358_CR21","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1007\/s00262-012-1350-1","volume":"62","author":"AD Kaiser","year":"2013","unstructured":"Kaiser AD, Gadiot J, Guislain A, Blank CU. Mimicking homeostatic proliferation in vitro generates T cells with high anti-tumor function in non-lymphopenic hosts. Cancer Immunol Immunother. 2013;62:503\u201315.","journal-title":"Cancer Immunol Immunother"},{"key":"358_CR22","doi-asserted-by":"publisher","first-page":"187","DOI":"10.4049\/jimmunol.1300331","volume":"191","author":"MM Tejera","year":"2013","unstructured":"Tejera MM, Kim EH, Sullivan JA, Plisch EH, Suresh M. FoxO1 controls effector-to-memory transition and maintenance of functional CD8 T cell memory. J Immunol. 2013;191:187\u201399.","journal-title":"J Immunol"},{"key":"358_CR23","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1038\/cgt.2014.48","volume":"21","author":"CK Zoon","year":"2014","unstructured":"Zoon CK, Seitelman E, Keller S, Graham L, Blevins TL, Dumur CI, et al. Expansion of melanoma-specific lymphocytes in alternative gamma chain cytokines: gene expression variances between T cells and T-cell subsets exposed to IL-2 versus IL-7\/15. Cancer Gene Ther. 2014;21:441\u20137.","journal-title":"Cancer Gene Ther"},{"key":"358_CR24","doi-asserted-by":"publisher","first-page":"2090","DOI":"10.1172\/JCI77746","volume":"125","author":"KN Pollizzi","year":"2015","unstructured":"Pollizzi KN, Patel CH, Sun IH, Oh MH, Waickman AT, Wen J, et al. mTORC1 and mTORC2 selectively regulate CD8+ T cell differentiation. J Clin Invest. 2015;125:2090\u2013108.","journal-title":"J Clin Invest"},{"key":"358_CR25","doi-asserted-by":"publisher","first-page":"1206","DOI":"10.1016\/j.celrep.2015.12.095","volume":"14","author":"L Zhang","year":"2016","unstructured":"Zhang L, Tschumi BO, Lopez-Mejia IC, Oberle SG, Meyer M, Samson G, et al. Mammalian target of rapamycin complex 2 controls CD8 T cell memory differentiation in a Foxo1-dependent manner. Cell Rep. 2016;14:1206\u201317.","journal-title":"Cell Rep"}],"container-title":["Journal for ImmunoTherapy of Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s40425-018-0358-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s40425-018-0358-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s40425-018-0358-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,9,25]],"date-time":"2020-09-25T17:43:34Z","timestamp":1601055814000},"score":1,"resource":{"primary":{"URL":"https:\/\/jitc.bmj.com\/lookup\/doi\/10.1186\/s40425-018-0358-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,5,29]]},"references-count":25,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018,12]]}},"alternative-id":["358"],"URL":"https:\/\/doi.org\/10.1186\/s40425-018-0358-2","relation":{},"ISSN":["2051-1426"],"issn-type":[{"value":"2051-1426","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,5,29]]},"assertion":[{"value":"25 April 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 May 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 May 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"All mouse work was reviewed and approved by the University of Wisconsin and William S. Middleton Memorial VA Hospital and VA Ann Arbor Healthcare Animal Care and Use Committees.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The authors declare that they have no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Publisher\u2019s Note"}}],"article-number":"41"}}